Last Price$33.90.6%
Market Cap$15.2B
LTM Dividend per Share (DPS)
$0.8
5Y avg
$0.8
Biotechnology industry
median
$0.0
Stock quality & Intrinsic value
6/10
4.3% undervalued
Royalty Pharma plc Dividend per Share (DPS)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|
| Dividend per Share (DPS) | $0.9 | $0.6 | $0.7 | $0.8 | $0.8 |
Overvalued or undervalued?
Check the intrinsic value for RPRX
and see if it's the right time to invest.
Royalty Pharma plc (RPRX) Dividend per Share (DPS) comparison analysis
General
LTM Dividend per Share (DPS)
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Royalty Pharma plcRPRX
$0.8
(3.8%)
(43.7%)
37.9%
Median Peer Set
$0.0
18.9%
(47.6%)
0.4%
Novo Nordisk A/SNVO
$9.9
24.9%
142.8%
34.8%
argenx SEARGX
$0.0
198.6%
(60.5%)
(24.1%)
BeiGene, Ltd.BGNE
$0.0
73.7%
(56.5%)
(35.9%)
BioNTech SEBNTX
$0.0
(77.4%)
(89.7%)
24.4%
Incyte CorporationINCY
$0.0
14.8%
(94.0%)
0.8%
Regeneron Pharmaceuticals, Inc.REGN
$0.0
8.3%
10.4%
31.1%
Summit Therapeutics Inc.SMMT
$0.0
N/A
(68.7%)
N/A
United Therapeutics CorporationUTHR
$0.0
23.6%
25.7%
41.5%
Vertex Pharmaceuticals IncorporatedVRTX
$0.0
11.7%
N/A
(4.9%)
Alnylam Pharmaceuticals, Inc.ALNY
$0.0
23.0%
(38.6%)
(12.4%)
RPRX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1,652.4 0.0% | 1,877.4 13.6% | 1,597.9 (14.9%) | 1,794.9 12.3% | 1,814.3 1.1% | 2,122.0 17.0% | 2,289.5 7.9% | 2,237.2 (2.3%) | 2,354.6 5.2% | 2,264.0 (3.8%) |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 33.3 | 136.0 | 1,019.3 | 88.1 | 23.0 | 5.7 | 560.7 | 0.0 |
% margin | 1,652.4 100.0% | 1,877.4 100.0% | 1,564.7 97.9% | 1,658.9 92.4% | 794.9 43.8% | 2,033.9 95.8% | 2,266.5 99.0% | 2,231.5 99.7% | 1,793.9 76.2% | 2,264.0 100.0% |
| Operating Expenses | 790.0 | 1,086.3 | 658.2 | 430.4 | (808.9) | 527.0 | 858.7 | 1,314.3 | 862.4 | 971.0 |
| Research & Development Expenses (R&D) | 98.4 | 91.0 | 117.9 | 392.6 | 83.0 | 26.0 | 200.1 | 177.1 | 52.0 | 2.0 |
| Selling, General & Administrative Expenses (SG&A) | 121.4 | 69.5 | 106.4 | 61.9 | 103.4 | 182.0 | 182.8 | 227.3 | 249.7 | 237.0 |
% margin | 794.3 48.1% | 722.9 38.5% | 939.7 58.8% | 1,364.4 76.0% | 2,623.2 144.6% | 1,595.0 75.2% | 1,430.7 62.5% | 977.5 43.7% | 1,492.2 63.4% | 1,292.0 57.1% |
| Interest Income | 0.0 | 0.0 | 6.8 | 24.4 | 22.3 | 28.4 | 53.5 | 78.3 | 72.3 | 0.0 |
| Interest Expense | 224.4 | 238.9 | 247.3 | 280.0 | 268.6 | 157.0 | 166.1 | 188.0 | 187.2 | 226.0 |
| Pre-tax Income | 758.7 | 761.9 | 1,343.2 | 1,517.9 | 2,461.4 | 1,702.0 | 1,241.2 | 230.1 | 1,700.1 | 1,331.0 |
% effective tax rate | 177.3 23.4% | 196.0 25.7% | 542.7 40.4% | 433.4 28.6% | 349.3 14.2% | 1,147.0 67.4% | 762.4 61.4% | 187.2 81.4% | 0.0 0.0% | 472.0 35.5% |
% margin | 581.4 35.2% | 565.9 30.1% | 1,210.0 75.7% | 1,377.7 76.8% | 2,348.5 129.4% | 495.2 23.3% | 478.8 20.9% | 42.8 1.9% | 1,134.8 48.2% | 859.0 37.9% |
| EPS | 0.96 | 0.93 | 3.42 | 3.89 | 6.42 | 1.32 | 1.15 | 0.10 | 3.41 | 1.92 |
| Diluted EPS | 0.96 | 0.93 | 3.42 | 3.89 | 6.42 | 1.32 | 1.15 | 0.10 | 2.53 | 1.45 |
% margin | 862.4 52.2% | 1,069.0 56.9% | 973.0 60.9% | 1,397.7 77.9% | 2,647.1 145.9% | 1,683.5 79.3% | 1,453.7 63.5% | 928.6 41.5% | 1,887.3 80.2% | 1,292.0 57.1% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Royalty Pharma plc's Dividend per Share (DPS)?
As of today, Royalty Pharma plc's last 12-month Dividend per Share (DPS) is $0.8, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Royalty Pharma plc's Dividend per Share (DPS) growth rate?
Over the last year, Royalty Pharma plc's Dividend per Share (DPS) growth was 7.9%. The average annual Dividend per Share (DPS) growth rates for Royalty Pharma plc have been 13.0% over the past three years, (12.3%) over the past five years.